Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease Treated With Metformin and Sulfonylurea
In this medfyle
Expert commentary by Vivian Fonseca, MD
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the ENDO 2021 and presented by:
Matthew J. Budoff, MD
Lundquist Institute, Torrance, CA, USA
The content is produced by Infomedica, the official reporting partner of ENDO 2021. The summary text was drafted by Patrick Moore, PhD, and reviewed by Marco Gallo, MD, an independent external expert, and approved by Raghu Mirmira, MD, PhD, the scientific editor of the program.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Vivian Fonseca, MD
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology Tulane University Health Sciences Center
New Orleans, LA, USA
About the Expert
Vivian Fonseca, MD
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology Tulane University Health Sciences Center
New Orleans, LA, USA
Vivian A. Fonseca, MD, FRCP, is Professor of Medicine, Assistant Dean for Clinical Research, the Tullis-Tulane Alumni Chair in Diabetes, and chief of the Section of Endocrinology at Tulane University Medical Center in New Orleans, Louisiana. He is a Past President for Science and Medicine of the American Diabetes Association (2012), and has served on the ADA Board of Directors and several committees. He has served on the Board of Directors of the American Association of Clinical Endocrinologists (AACE), and the Board of Trustees of the American College of Endocrinology.
He plays a significant role in Clinical Research as Assistant Dean at Tulane University, and in its partnership with the Louisiana Clinical and Translational Science (LACaTS) Program. He is the Medical Director of the Tulane Clinical Trials Unit and Director of the Research Professional Development Core, which runs the Masters in Science in Clinical Research program.
Dr. Fonseca’s research interests include the prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease, particularly on the role of inflammation and other novel risk factors. He has a research program evaluating inflammation in diabetes, and using technology to improve diabetes care in underprivileged populations, especially the use of a new diabetes risk engine in clinical practice. He is the Louisiana PI of the All of Us Program, Southern Network and Co – PI of REACHnet a large network that conducts research utilizing electronic health records of over 2 million people across several states.
Dr Fonseca has a strong interest in facilitating clinical research and developing the next generation of translational researchers.
References
1. Montvida O, Shaw J, Atherton JJ, et al. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes. Diabetes Care. 2018;41(1):69-78.
2. Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586-1593.
3. Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020;383(15):1425-1435.
4. Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018;206:11-23.
